Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course

Since its licensing in 1971, the synthetic compound inosine pranobex has been effectively combating viral infections, including herpes zoster, varicella, measles, and infections caused by the herpes simplex virus, human papillomavirus, Epstein–Barr virus, cytomegalovirus, and respiratory viruses. Wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Beran, Jiří, Špajdel, Marián, Slíva, Jiří
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619495/
https://www.ncbi.nlm.nih.gov/pubmed/34835052
http://dx.doi.org/10.3390/v13112246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619495/
https://www.ncbi.nlm.nih.gov/pubmed/34835052
http://dx.doi.org/10.3390/v13112246

Ejemplares similares